Rankings
▼
Calendar
GH (Guardant Health, Inc.) Stock Financials & Earnings | Market Cap Arena
GH
Guardant Health, Inc.
Mkt Cap
$12B
Healthcare
·
Medical - Diagnostics & Research
·
🇺🇸 United States
·
NASDAQ
Revenue (TTM)
$982M
Net Income (TTM)
-$416M
EPS (TTM)
-$3.31
Free Cash Flow (TTM)
-$221M
Gross Margin
64.5%
Op. Margin
-44.5%
Net Margin
-42.4%
FCF Margin
-22.5%
P/S Ratio (TTM)
12.2x
P/E Ratio (TTM)
—
YoY Rev Growth
+32.9%
Employees
—
Earnings Reports
▶
Q4 2025
Browse All Reports
Quarterly
FY
Revenue & Profitability
Revenue
Gross Profit
Operating Income
Quarter
Revenue
Gross Profit
Op. Income
Q1 23
$129M
$76M
-$134M
Q2 23
$137M
$83M
-$120M
Q3 23
$143M
$85M
-$114M
Q4 23
$155M
$236M
-$198M
Q1 24
$168M
$103M
-$100M
Q2 24
$177M
$105M
-$101M
Q3 24
$191M
$117M
-$117M
Q4 24
$202M
$124M
-$126M
Q1 25
$203M
$129M
-$111M
Q2 25
$232M
$151M
-$106M
Q3 25
$265M
$172M
-$99M
Q4 25
$281M
$182M
-$121M
marketcaparena.com
Valuation
P/S Ratio
P/E Ratio
Quarter
P/S
P/E
Q1 23
24.8x
—
Q2 23
23.4x
—
Q3 23
22.3x
—
Q4 23
21.2x
—
Q1 24
19.8x
—
Q2 24
18.5x
—
Q3 24
17.2x
—
Q4 24
16.2x
—
Q1 25
15.4x
—
Q2 25
14.4x
—
Q3 25
13.2x
—
Q4 25
12.2x
—
marketcaparena.com
Operating Cash Flow
Operating Cash Flow
Free Cash Flow
Quarter
Operating CF
Free CF
Q1 23
-$74M
-$82M
Q2 23
-$94M
-$101M
Q3 23
-$78M
-$80M
Q4 23
-$79M
-$83M
Q1 24
-$30M
-$37M
Q2 24
-$94M
-$99M
Q3 24
-$51M
-$55M
Q4 24
-$65M
-$83M
Q1 25
-$63M
-$67M
Q2 25
-$60M
-$66M
Q3 25
-$35M
-$46M
Q4 25
-$14M
-$42M
marketcaparena.com
Capital Expenditures
CapEx
Quarter
CapEx
Q1 23
$8M
Q2 23
$7M
Q3 23
$2M
Q4 23
$4M
Q1 24
$7M
Q2 24
$5M
Q3 24
$4M
Q4 24
$19M
Q1 25
$4M
Q2 25
$6M
Q3 25
$10M
Q4 25
$28M
marketcaparena.com
OpEx vs Revenue Growth (YoY)
Revenue Growth
OpEx Growth
Quarter
Revenue Growth
OpEx Growth
Q1 23
+33.9%
+19.7%
Q2 23
+25.7%
+7.2%
Q3 23
+21.8%
-2.1%
Q4 23
+22.2%
+29.1%
Q1 24
+30.9%
+2.1%
Q2 24
+29.2%
+8.2%
Q3 24
+33.9%
+20.4%
Q4 24
+30.2%
-7.0%
Q1 25
+20.8%
+17.3%
Q2 25
+30.9%
+21.8%
Q3 25
+38.5%
+17.9%
Q4 25
+39.4%
+22.7%
marketcaparena.com
Stock-Based Compensation
SBC ($)
% of Revenue
Quarter
SBC ($)
% of Revenue
Q1 23
$22M
17.3%
Q2 23
$22M
16.3%
Q3 23
$22M
15.3%
Q4 23
$24M
15.7%
Q1 24
$27M
16.0%
Q2 24
$27M
15.4%
Q3 24
$50M
26.0%
Q4 24
$36M
18.0%
Q1 25
$38M
18.6%
Q2 25
$42M
18.3%
Q3 25
$43M
16.1%
Q4 25
$0
0.0%
marketcaparena.com
OpEx Breakdown
R&D
G&A
S&M
Quarter
R&D
G&A
S&M
Q1 23
$93M
$40M
$76M
Q2 23
$90M
$42M
$71M
Q3 23
$94M
$36M
$69M
Q4 23
$90M
$38M
$79M
Q1 24
$84M
$39M
$80M
Q2 24
$83M
$40M
$82M
Q3 24
$87M
$49M
$98M
Q4 24
$94M
$52M
$105M
Q1 25
$89M
$47M
$104M
Q2 25
$87M
$50M
$120M
Q3 25
$90M
$53M
$127M
Q4 25
$98M
$61M
$143M
marketcaparena.com
Revenue Segments
Biopharma & Data
Licensing & Other
Oncology
Screening
Quarter
Biopharma & Data
Licensing & Other
Oncology
Screening
Q1 25
$45M
$2M
$151M
$6M
Q2 25
$56M
$3M
$159M
$15M
Q3 25
$55M
$2M
$184M
$24M
Q4 25
$54M
$2M
$190M
$35M
marketcaparena.com
Revenue by Geography
Non-US
United States
Quarter
Non-US
United States
Q1 23
$10M
$119M
Q2 23
$8M
$129M
Q3 23
$7M
$136M
Q4 23
$12M
$143M
Q1 24
$11M
$157M
Q2 24
$9M
$168M
Q3 24
$11M
$180M
Q4 24
$10M
$192M
Q1 25
$10M
$194M
Q2 25
$15M
$217M
Q3 25
$16M
$249M
Q4 25
$18M
$264M
marketcaparena.com
War Chest
Cash & Equivalents
Short-Term Investments
Quarter
Cash
Short-term Investments
Total
Q1 23
$224M
$713M
$937M
Q2 23
$271M
$954M
$1.2B
Q3 23
$457M
$697M
$1.2B
Q4 23
$1.1B
$35M
$1.2B
Q1 24
$1.1B
$0
$1.1B
Q2 24
$1.0B
$0
$1.0B
Q3 24
$688M
$311M
$999M
Q4 24
$526M
$314M
$840M
Q1 25
$699M
$0
$699M
Q2 25
$629M
$0
$629M
Q3 25
$580M
$0
$580M
Q4 25
$378M
$823M
$1.2B
marketcaparena.com
Shares Outstanding
Shares Outstanding
Quarter
Shares (Diluted)
QoQ Change
Q1 23
103M
+0.1%
Q2 23
109M
+6.0%
Q3 23
118M
+8.2%
Q4 23
119M
+0.7%
Q1 24
122M
+2.7%
Q2 24
122M
+0.6%
Q3 24
123M
+0.5%
Q4 24
124M
+0.6%
Q1 25
124M
+0.1%
Q2 25
124M
+0.2%
Q3 25
125M
+1.0%
Q4 25
129M
+2.7%
marketcaparena.com
Revenue Per Employee
Revenue / Employee
Year
Revenue/Employee
Employees
FY 16
—
—
FY 17
—
—
FY 18
$200K
454
FY 19
$345K
622
FY 20
$332K
864
FY 21
$272K
1K
FY 22
$251K
2K
FY 23
$317K
2K
FY 24
$366K
2K
FY 25
$41K
24K
marketcaparena.com